Shattuck Labs, Inc.
STTK
$-0.06
Change (1 day)
$11.76
Year High
$1.15
Year Low
Categories
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
P/E ratio for Shattuck Labs, Inc. (STTK)
P/E ratio as of 2023: -3.48
According to Shattuck Labs, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.48. At the end of 2022 the company had a P/E ratio of -0.97.
P/E ratio history for Shattuck Labs, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.48 |
| 2022 | -0.97 |
| 2021 | -8.07 |
| 2020 | -61.77 |
| 2019 | -33.82 |
| 2018 | -39.40 |